Gene Expression Profiles in Muscle After Immunisation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical study is part of the BIOVACSAFE project which is funded by the Innovative Medicine Initiative. In this study we will take a small muscle biopsy in order to identify any differences in the response around the actual site of injection compared with responses we measure in blood at the same time.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Flu Vaccine Study in Neuromuscular Patients 2011

NCT01422200

Duchenne Muscular Dystrophy Spinal Muscular Atrophy Congenital Muscular Dystrophy

COMPLETED PHASE4

Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells

NCT03644498

Cancer

COMPLETED

A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults

NCT00942071

Influenza

COMPLETED PHASE1

Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines

NCT01674205

Influenza, Human

COMPLETED PHASE1

PET-CT Scans in Healthy Volunteers After Flu Vaccination

NCT00769002

Flu

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fluad

Participants receive one dose of Fluad vaccine

Group Type ACTIVE_COMPARATOR

Fluad

Intervention Type BIOLOGICAL

Fendrix

Participants receive one dose of Fendrix vaccine

Group Type ACTIVE_COMPARATOR

Fendrix

Intervention Type BIOLOGICAL

Placebo

Participants receive one dose of saline placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fluad

Intervention Type BIOLOGICAL

Fendrix

Intervention Type BIOLOGICAL

Placebo

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The participant is able to read and understand the Informed Consent Form (ICF), and understand study procedures.
2. The participant has signed the ICF.
3. Healthy male participants aged 18-45 years inclusive.
4. BMI between 19-27 kg/m2.
5. Pre-immunised with Hepatitis B vaccine
6. Hepatitis B sAb positive (evidence of vaccine-induced immunity)
7. Hepatitis B sAg and cAb negative (evidence of lack of prior/current HBV infection)
8. Hepatitis C and HIV seronegative.
9. Available for follow-up for the duration of the study.
10. Agree to abstain from donating blood during the study.
11. The participant is, in the opinion of the investigator, healthy on the basis of a, medical history, a symptom directed medical examination and vital signs.

Exclusion Criteria

1. History of hypersensitivity to any of the vaccine components or a history of any allergy that in the opinion of the investigator would contraindicate participant participation
2. Clinically significant psychiatric, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological (particularly myasthenia gravis), immunological, or haematological disease or abnormality, as determined by the study physician.
3. Known immune or coagulation disorder or clinically significant abnormalities of platelets, Hb or coagulation on screening labs
4. Known allergy to injected local anaesthetics
5. Unwilling to undergo muscle biopsies
6. Use of steroids or immunosuppressive/immunomodulating drugs either orally or parenterally within 3 months of visit 1.
7. Currently participating in a clinical trial with an investigational or non- investigational drug or device, or has participated in another clinical trial within the 3 months preceding the study.
8. Any condition that, in the investigator's opinion, compromises the participant's ability to meet protocol requirements or to complete the study.
9. Receipt of blood products or immunoglobin, within 3 months of visit 1.
10. Unable to read and speak English to a fluency level adequate for the full comprehension of procedures required in participation and consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes